MBG.F · Marinomed Biotech AG

-

Please sign in to comment on MBG.F

1 Comment

Admin

4 years ago

Marinomed Biotech AG is currently in a long term downtrend where the price is trading 0.7% below its 200 day moving average.

From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 25.8.

Marinomed Biotech AG's total revenue rose by 67.7% to $3M since the same quarter in the previous year.

Its net income has dropped by 24.7% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 351.3% to $-3M since the same quarter in the previous year.

Based on the above factors, Marinomed Biotech AG gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	DE0007100000
Sector	Consumer Cyclical
Industry	Auto Manufacturers

Market Cap	49B
PE Ratio	4.96
Target Price	67.2086
Dividend Yield	8.5%
Beta	1.0

ABOUT

Marinomed Biotech AG

Mercedes-Benz Group AG operates as an automotive company in Germany and internationally. It operates through Mercedes-Benz Cars, Mercedes-Benz Vans, and Mercedes-Benz Mobility segments. The company develops, manufactures, and sells cars and vans under the Mercedes-Benz, Mercedes-AMG, Mercedes-Maybach, G-Class brands, as well as related spare parts and accessories. It also provides financing, leasing, vehicle subscription and rental, fleet management, insurance brokerage, and mobility services, as well as digital services for charging and payment. The company was formerly known as Daimler AG and changed its name to Mercedes-Benz Group AG in February 2022. Mercedes-Benz Group AG was founded in 1886 and is headquartered in Stuttgart, Germany.

MBG.F · Marinomed Biotech AG

-

Marinomed Biotech AG

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Marinomed Biotech AG using a moving average strategy